Effect of high versus low oral doses of valacyclovir on herpes simplex virus-1 DNA shedding into tears of latently infected rabbits.
OBJECTIVE
To assess the effect of high doses of valacyclovir (VCV) on HSV-1 DNA shedding into tears of latently infected rabbits.


METHODS
Three oral doses of VCV were tested. Corneas were inoculated with HSV-1, and latent infection was allowed to establish. Starting on postinoculation (PI) day 28, tear swabs were collected once daily for 6 consecutive days before treatment. The rabbits were placed in five balanced groups: group 1 had no treatment, group 2 received placebo, group 3 received 7 mg/kg VCV, group 4 received 70 mg/kg, and group 5 received 140 mg/kg. The treatment was administered by oral gavage twice daily, starting on PI day 36 and continuing for 14 days. The ocular swabs were collected beginning on PI day 40 and continuing for 10 days.


RESULTS
The mean copy number of HSV-1 DNA before treatment was 370+/-70, 569+/-273, 368+/-86, 408+/-108, and 396+/-91, and the mean HSV-1 DNA copy number after treatment was 232+/-183, 564+/-186, 518+/-122, 67+/-63, and 13+/-7 in groups 1 to 5, respectively.


CONCLUSIONS
There was no observable toxicity in any group. The 70- and 140-mg/kg doses of VCV significantly reduced the HSV-1 DNA copy number, compared with that of the other three groups. A daily dose of 500 mg (approximately 7 mg/kg) VCV in healthy human volunteers did not suppress HSV-1 DNA shedding in tears and saliva. Thus, higher doses of VCV may be necessary to reduce asymptomatic shedding in healthy human subjects.
Kumar
Manish
M
Department of Ophthalmology, Neuroscience Center of Excellence, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
Kaufman
Herbert E
HE
Clement
Christian
C
Bhattacharjee
Partha S
PS
Huq
Tashfin S
TS
Varnell
Emily D
ED
Thompson
Hilary W
HW
Hill
James M
JM
D000212:Acyclovir / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D004279:DNA, Viral / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D018628:Gene Dosage; D006561:Herpes Simplex / Q000188:drug therapy / Q000635:transmission / Q000821:virology; D018259:Herpesvirus 1, Human / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development; D011817:Rabbits; D013666:Tears / Q000187:drug effects / Q000821:virology*; D000077483:Valacyclovir; D014633:Valine / Q000031:analogs & derivatives* / Q000494:pharmacology; D017735:Virus Latency
D000998:Antiviral Agents; D004279:DNA, Viral; D014633:Valine; D000077483:Valacyclovir; D000212:Acyclovir
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Jan;105(1):43-50
17703961
Antimicrob Agents Chemother. 2003 Aug;47(8):2438-41
12878501
Sex Transm Dis. 2008 Apr;35(4):383-6
18362859
Schizophr Res. 2009 Feb;107(2-3):147-9
19008077
J Virol. 2008 Aug;82(16):8230-4
18550674
Invest Ophthalmol Vis Sci. 2005 Jan;46(1):241-7
15623779
J Infect Dis. 2008 Dec 15;198(12):1804-8
18928378
Trans Am Ophthalmol Soc. 2000;98:285-303
11190029
Antimicrob Agents Chemother. 1995 Dec;39(12):2759-64
8593015
Drugs. 2000 Apr;59(4):839-63
10804039
J Infect Dis. 2004 Oct 15;190(8):1374-81
15378428
Eur J Neurol. 2009 Apr;16(4):457-60
19187258
J Cutan Med Surg. 2003 Sep-Oct;7(5):372-81
14505192
J Infect Dis. 2008 May 1;197(9):1289-95
18422441
N Engl J Med. 2004 Jan 1;350(1):11-20
14702423
Semin Ophthalmol. 2008 Jul-Aug;23(4):249-73
18584563
J Virol. 2009 Nov;83(22):11857-61
19740997
J Antimicrob Chemother. 2001 Jun;47(6):855-61
11389118
Cornea. 1999 Nov;18(6):693-9
10571301
Arch Neurol. 2006 Jul;63(7):940-2
16682531
Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5601-8
19608530